KYKangjie Yu

Kangjie Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kangjie Yu has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Linni Fan

    State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Air Force Medical University, Xi'an, China

    3 shared publications
  • Shuangping Guo

    State Key Laboratory of Tumor Biology, Department of Pathology, the Basic Medicine Science and Xi Jing Hospital, the Fourth Military Medical University, Xi'an, Shaan Xi Province, 710032, China

    3 shared publications
  • Zhe Wang

    Department of Pathology, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Xijing Hospital, School of Basic Medicine, Fourth Military Medical University, Xi’an, China

    3 shared publications
  • Jia Chai

    State Key Laboratory of Cancer Biology, Department of Pathology, Xijing hospital, Fourth Military Medical University, Xi'an, China

    2 shared publications
  • Kaijing Wang

    Department of Pathology, Xijing Hospital, Air Force Medical University, Xi'an, China

    2 shared publications
  • Peifeng Li

    Department of Pathology, The 960th Hospital of the People’s Liberation Army (PLA) Joint Logistic Support Force

    2 shared publications

Latest Publications

  • TOPK: A new predictor of the therapeutic response to neoadjuvant chemotherapy and prognosis in triple-negative breast cancer

    by Kaijing Wang, Jia Chai, Junpeng Xu, Jie Wei, Peifeng Li, Yixiong Liu, Jing Ma, Tianqi Xu, Danhui Zhao, Kangjie Yu, et al.


  • Open Access

    Expression of RSK4, CD44 and MMP-9 is upregulated and positively correlated in metastatic ccRCC

    by Jing Ma, Mingyang Li, Jia Chai, Kaijing Wang, Peifeng Li, Yixiong Liu, Danhui Zhao, Junpeng Xu, Kangjie Yu, Qingguo Yan, et al.

    Background: To investigate the expression and function of RSK4, MMP-9 and CD44 in primary clear cell renal cell carcinoma (primary ccRCC) and metastatic clear cell renal cell carcinoma (metastatic ccRCC), as well as the correlation with clinicopathological features of patients. Method: The expression levels of RSK4, CD44 and MMP-9 in 52 primary ccRCC samples and 48 metastatic ccRCC samples were detected by immunohistochemistry, and the relationship between RSK4, CD44 and MMP-9 expression and clinicopathological features as well as prognosis of metastatic ccRCC patients was statistically analysed. Ectopic RSK4 expression in ccRCC cell lines was performed to determine its effect on cell cycle regulation, tumour invasiveness, and metastatic capability. Results: The positive rates of RSK4, MMP-9 and CD44 expression in metastatic ccRCC tissues were 75, 68.75 and 91.7%, respectively, while the rates in primary ccRCC tissues were 44.2, 34.6 and 69.2%, respectively. Thus, the positive rates in metastatic ccRCC were higher than those in primary ccRCC (PRSK4 = 0. 002; PMMP-9 = 0. 002; PCD44 = 0. 001). However, the expression of RSK4, CD44 and MMP-9 was unrelated to age, gender, or metastatic sites (P > 0.05) but was related to WHO/ISUP nucleolar grade (PRSK4 = 0.019; PCD44 = 0.026; PMMP-9 = 0.049). In metastatic ccRCC, expression among the three proteins showed a positive correlation (P = 0.008). Moreover, expression between RSK4 and CD44 (P = 0.019) and MMP-9 and CD44 (P = 0.05) also showed positive correlations, whereas RSK4 and MMP-9 showed no significant correlation (P = 1.00). Molecular studies showed that overexpression of RSK4 could enhance the invasive and migratory abilities of ccRCC cell lines through the regulation of CD44 and MMP-9 expression and vice versa. Conclusions: The overexpression of RSK4, MMP-9 and CD44 is associated with the invasion and metastasis of ccRCC, indicating that they could be potential prognostic factors and serve as new potential therapeutic targets for ccRCC.


  • Open Access

    MET-overexpressing myxofibrosarcoma frequently exhibit polysomy of chromosome 7 but not MET amplification, especially in high-grade cases: clinical and pathological review of 30 myxofibrosarcoma cases

    by Shirong Ma, Linni Fan, Yixiong Liu, Yingmei Wang, Kangjie Yu, Lifeng Wang, Na Fang, Fang Liu, Shuangping Guo, Zhe Wang

    Myxofibrosarcoma (MFS) is one of the most common soft tissue sarcomas. Previous studies have shown that MET protein overexpressed in MFS patients and can serve as a prognostic factor. The reasons for MET protein overexpression include amplification of the MET gene, which is located on chromosome 7q. Triggered by an index case harboring chromosome 7 polysomy rather than MET gene amplification in myxofibrosarcoma, we investigated chromosome 7 polysomy in more cases. Immunohistochemistry and fluorescence in situ hybridization (FISH) were performed in 30 MFS cases (including 2 epithelioid variant) to detect the expression of MET protein and gene status. MET was overexpressed in 14 cases out of 30, while thirteen cases were in higher FNCLCC grades (Grade 2–3). FISH showed that 11 cases having 3 signals on average of Met and more than 3 signals (Mean: 4.6) of centromere 7q (CEP7q). The MET/CEP7 ratio was about 0.65 on average, suggesting that chromosome 7 polysomy, rather than Met gene amplification, leading to the overexpression of MET protein in MFS. MET overexpression and chromosome 7 polysomy are positively correlated with higher Ki-67 index and higher grade and might have a high risk of local recurrence and metastasis. It might reveals another explain of MET overexpression in myxofibrosarcoma, providing a clue for the therapy of MFS.